| DGX |
Report |
Revenue |
IN-LINE |
pred ~$2.990B vs. cons $2.974B |
MEDIUM |
| DGX |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$2.860 vs. cons $2.836 |
MEDIUM |
| DGX |
Report |
Organic requisition-volume growth |
BEAT |
pred ~8.5% vs. cons 7.8% |
MEDIUM |
| DGX |
Guide |
FY2026 revenue |
UNCHANGED |
guide ~$11.78B-$11.90B vs. cons $11.850B |
MEDIUM |
| DGX |
Guide |
FY2026 adjusted diluted EPS |
UNCHANGED |
guide ~$10.63-$10.83 vs. cons $10.766 |
MEDIUM |
| DGX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| DGX |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implied H2 EPS below consensus |
LOW |